|3,5,7-三羟基-2-(4-甲氧基苯基)-8-(3-甲基丁-2-烯-1-基)-4H-苯并吡喃-4-酮|CsnPharm

CAS No.: 118525-40-9

淫羊藿素 Catalog No. CSN13947

Synonyms: Anhydroicaritin;淫羊藿素

Icaritin is a flavonoid that can enhance osteoblastic differentiation of mesenchymal stem cells (MSCs) and display a role of estrogen-like activities. Icaritin could be extracted from the roots of Epimedium brevicornu Maxim with anti-cancer effects.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Icaritin is a prenylflavonoid derivative from Epimedium Genusis. Icaritin potently inhibited proliferation of K562 cells (IC50 was 8 µM) and primary CML cells (IC50 was 13.4 µM for CML-CP and 18 µM for CML-BC), induced CML cells apoptosis and promoted the erythroid differentiation of K562 cells with time-dependent manner. Furthermore, Icaritin was able to suppress the growth of primary CD34+ leukemia cells (CML-chronic myeloid leukemia) and Imatinib-resistant cells, and to induce apoptosis^[3]. At concentrations of 2-3 μM, icaritin induced cell cycle arrest at the G(2)/M phase accompanied by a down-regulation of the expression levels of the G(2)/M regulatory proteins such as cyclinB, cdc2 and cdc25C. Icaritin at concentrations of 4-5 μM, however, induced apoptotic cell death characterized by the accumulation of the annexin V- and propidium iodide-positive cells, cleavage of poly ADP-ribose polymerase (PARP) and down-regulation of the Bcl-2 expression. In addition, icaritin also induced a sustained phosphorylation of extracellular signal-regulated kinase (ERK) in these breast cancer cells^[4]. Icaritin can effectively decrease tumor burden of murine B16F10 melanoma and MC38 colorectal tumors in a T-cell dependent manner^[5]. Icaritin inhibited the viability of U87 and T98G cells in a dose-dependent manner. Icaritin exerted inhibitory effects on cell viability and glycolysis in GBM cells, which was mediated by the IL-6/Stat3 pathway^[6].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03236649	Hepatocellular Carcinoma (HCC)	Phase 3	Not yet recruiting	August 2019	-
NCT03236636	Hepatocellular Carcinoma (HCC)	Phase 3	Not yet recruiting	August 2019	-
NCT02931305	Osteoporosis ... more >>Cardiovascular Disease Collapse <<	Phase 1	Unknown	October 2017	Singapore ... more >> Investigational Medicine Unit, National University Health System Recruiting Singapore, Singapore, 117599 Contact: Pei Ling Tan 6601 2534 angelia_pei_ling_tan@nuhs.edu.sg Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.7146 mL
- 13.5729 mL
- 27.1459 mL
- 5 mM
- 0.5429 mL
- 2.7146 mL
- 5.4292 mL
- 10 mM
- 0.2715 mL
- 1.3573 mL
- 2.7146 mL

技术信息

CAS号

118525-40-9

储存条件

粉末: Inert atmosphere,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C21H20O6

运输

蓝冰

分子量

368.38

别名

Anhydroicaritin;淫羊藿素

溶解度

DMSO	13.0 mg/mL (35.3 mM)
Water	Insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03236649	Hepatocellular Carcinoma (HCC)	Phase 3	Not yet recruiting	August 2019	-
NCT03236636	Hepatocellular Carcinoma (HCC)	Phase 3	Not yet recruiting	August 2019	-
NCT02931305	Osteoporosis ... more >>Cardiovascular Disease Collapse <<	Phase 1	Unknown	October 2017	Singapore ... more >> Investigational Medicine Unit, National University Health System Recruiting Singapore, Singapore, 117599 Contact: Pei Ling Tan 6601 2534 angelia_pei_ling_tan@nuhs.edu.sg Collapse <<
NCT02496949	Solid Tumors	Phase 1	Completed	-	China, Beijing ... more >> Cancer institute & hospital, chinese academy of medical sciences Beijing, Beijing, China, 100021 Collapse <<
NCT01278810	Metastatic Breast Cancer	Phase 1	Unknown	December 2011	China, Beijing ... more >> Cancer institute & hospital, chinese academy of medical sciences Recruiting Beijing, Beijing, China, 100021 Contact: Ying Fan, MD +86 010-87788120 fanying@csco.org.cn Collapse <<
NCT01972672	Hepatocellular Carcinoma (HCC)	Phase 2	Unknown	December 2015	China, Beijing ... more >> Cancer institute & hospital, chinese academy of medical sciences Recruiting Beijing, Beijing, China, 100021 Contact: Qing Li, MD +86 010-87788120 cheryliqing@aliyun.com Contact: Ying Fan, MD +86 010-87788120 fanying@csco.org.cn Principal Investigator: Yan Sun, MD Sub-Investigator: Qing Li, MD Beijing Shenogen Biomedical Co., Ltd Recruiting Beijing, Beijing, China, 102206 Contact: Shu Li, MD 13601388736 shu.li@shenogen.com Contact: Zhen Yuan 13437130194 zhen.yuan@shenogen.com China, Jiangsu NanJing PLA 81 Hospital Recruiting Nanjing, Jiangsu, China, 210002 Contact: Zhaojun Xia, MD xiazhaojun_summer@126.com Principal Investigator: Shukui Qin, MD Collapse <<

淫羊藿素 Catalog No. CSN13947

靶点选择性

请登录您的专属账户

确认信息